Hasil Pencarian - P. Rodriguez Otero

Perbaiki Hasil
  1. 1
    P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY

    P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY,... oleh K. Weisel, A. Wadlund, G. Gungor, E. Dergarabetian, C. Pacheco, N. Masurkar, P. Rodriguez-Otero

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Expansion of CD8+CD57+ T Cells in an Immunocompetent Patient with Acute Toxoplasmosis

    Expansion of CD8+CD57+ T Cells in an Immunocompetent Patient with Acute Toxoplasmosis oleh R. García-Muñoz, P. Rodríguez-Otero, A. Galar, J. Merino, J. J. Beunza, J. A. Páramo, R. Lecumberri

    Diterbitkan 2009-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY

    P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY oleh P Rodríguez-Otero, J San-Miguel, LD Anderson, Jr, S Lonial, A Truppel-Hartmann, J Sanford, E Rowe, TB Campbell, N Munshi

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL

    P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYEL... oleh P Rodríguez-Otero, N Shah, N Munshi, J Berdeja, S Jagannath, O Finney, N Martin, A Agarwal, E Rowe, T Campbell, J San-Miguel

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS

    TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS oleh JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

    P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES oleh A. Broijl, N. van de Donk, F. Bosch, M. V. Mateos, P. Rodriguez-Otero, A. Tucci, P. Ghia, A. Adang, P. Parren, I. Tuinhof, S. Umarale, B. Winograd, H. van der Vliet, A. Kater

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1

    S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FR... oleh M. C. Minnema, A. Krishnan, J. G. Berdeja, A. Oriol, N. W. van de Donk, P. Rodríguez-Otero, D. Morillo, M.-V. Mateos, L. J. Costa, J. Caers, D. Vishwamitra, J. Ma, S. Yang, B. W. Hilder, J. Tolbert, J. D. Goldberg, A. Chari

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1

    P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE... oleh N. W. C. J van de Donk, M C Minnema, J G Berdeja, A Oriol, A Krishnan, P Rodríguez-Otero, E Askari, M Mateos, L. J Costa, R Verona, J Ma, S Girgis, S Yang, B. W Hilder, J Russell, J. D Goldberg, A Chari

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON

    P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP... oleh M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS

    S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS oleh P. Rodriguez Otero, A. D’Souza, D. Reece, N. W. van de Donk, A. Chari, A. Krishnan, T. Martin, M. V. Mateos, D. Morillo, D. Hurd, L. Rosinol, A. S. Balari, R. Wäsch, D. Vishwamitra, S. X. Wang Lin, T. Prior, L. Vandenberk, M.-A. D. Smit, A. Oriol, B. Dholaria

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

    PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON oleh L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

    B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... oleh P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

    P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? oleh R Popat, A Badros, S Kumar, P Rodriguez-Otero, A Cohen, S Manier, P Voorhees, F Gay, R Rifkin, T Martin, A Chari, K Weisel, A Farooq, B Jeng, W Chng, H Lee, J Berdeja, V Jadhav, A Tosolini, L Eliason, A Palumbo, M Dimopoulos, S Lonial, S Trudel, P Richardson, E Terpos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

    B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY oleh P Rodriguez-Otero, B Dholaria, E Askari, D Reece, N van de Donk, A Chari, H Goldschmidt, A Krishnan, T Martin, M Mateos, D Morillo, C Rodriguez, L Rosinol, J San-Miguel, A Balari, R Wäsch, K Weisel, R Verona, S Lin, T Prior, M Wade, B Weiss, J Goldberg, A Oriol, P Hari

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

    B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS oleh M Mateos, P Hari, N Bahlis, A Chari, NWCJ van de Donk, B Dholaria, AL Garfall, H Goldschmidt, KM Kortüm, A Krishnan, T Martin, D Morillo, A Oriol, D Reece, C Rodriguez, P Rodríguez-Otero, JF San-Miguel, SZ Usmani, R Verona, SXW Lin, TJ Prior, M Wade, B Weiss, JD Goldberg, E Askari

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

    P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (B... oleh N. van de Donk, M.-V. Mateos, Y.C. Cohen, P. Rodriguez-Otero, B. Paiva, A.D. Cohen, T. Martin, A. Suvannasankha, D. Madduri, C. Corsale, J.M. Schecter, K.C. De Braganca, C.C. Jackson, H. Varsos, W. Deraedt, T. Roccia, P. Mistry, X. Xu, K. Li, E. Zudaire, M. Akram, L. Pacaud, I. Avivi, J. San-Miguel

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, FROM MONUMENTAL-1

    P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP... oleh N. van de Donk, L. Rasche, C. Touzeau, A. Chari, C. Schinke, M. Minnema, J. Berdeja, A. Oriol, P. Rodriguez-Otero, E. Askari, M. Mateos, L. Costa, J. Caers, A. Krishnan, D. Vishwamitra, J. Ma, X. Qin, K.S. Gries, K. Kato, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J. Goldberg, C. Heuck, P. Moreau, J. San-Miguel

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics

    Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... oleh S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB

    S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN CO... oleh N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, A. Chari

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

    P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES oleh L.-E. Tamariz-Amador, A. M. Battaglia, C. Maia, A. Zherniakova, C. Guerrero, A. Zabaleta, L. Burgos, C. Botta, M.-A. Fortuño, D. Alignani, L. Blanco, C. Grande, A. Manubens, J.-M. Arguiñano, C. Gomez, E. Perez-Persona, I. Olazabal, I. Oiartzabal, C. Panizo, F. Prosper, J. F. San Miguel, P. Rodriguez-Otero, E. Martín-Sánchez, B. Paiva, A. V.-N. H.-H. ASOVASNA

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: